Evidence map›Paper›PMID 34343111›Full record

ArticleAging2021

Computational research of mTORC1 inhibitor on cerebral ischemia-reperfusion injury.

Hui Li, Wenzhuo Yang, Zhenhua Wang, Xu Wang, Yulei Hao, Jianxin Xi, Han Lu, Zhishan Du, Jiachun Feng, Bao Zhang and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. TMAO as a Novel Predictor of Major Adverse Vascular Events and Recurrence in Patients with Large Artery Atherosclerotic Ischemic Stroke.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Hui LiDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.
Wenzhuo YangClinical College, Jilin University, Changchun, China.
Zhenhua WangClinical College, Jilin University, Changchun, China.
Xu WangDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.
Yulei HaoDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.
Jianxin XiClinical College, Jilin University, Changchun, China.
Han LuClinical College, Jilin University, Changchun, China.
Zhishan DuClinical College, Jilin University, Changchun, China.
Jiachun FengDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.
Bao ZhangDepartment of Urology Surgery, Aerospace Center Hospital, Beijing, China.
Di MaDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.
Jilin University · CNFirst Hospital of Jilin University · CNAerospace Center Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic stroke contributes to more than 80% of all strokes and has the four characteristics of high prevalence, high disability, high mortality, and high recurrence. Stroke is a preventable and controllable disease. In addition to controlling the primary disease, effective prevention and control measures need to be given to the occurrence and development of stroke. With the development and progress of modern treatment methods for ischemic stroke, the mortality and disability rate have decreased significantly. At present, the main treatment methods for ischemic stroke include thrombolysis, thrombus removal at the ultra-early stage, and treatment of improving collateral circulation in the acute phase. However, the ultra-early and early blood reperfusion involves reperfusion injury, which will cause secondary nerve damage, which is called cerebral ischemia/reperfusion injury (CIRI). Studies have found that autophagy is involved in the entire process of CIRI and can reduce the damage of CIRI. The mammalian target of Rapamycin (mTORC1) is the primary signal pathway regulating autophagy. And the mTORC1 inhibitor, Rapamycin, has been proved to exert neuroprotective effects in the ultra-early and early cerebral ischemia-reperfusion. Therefore, screening and designing mTORC1 inhibitors is very important to control reperfusion injury and reduce neuronal death and apoptosis. In this research, plenty of computer-assisted was applied to virtually screen and select potential mTORC1's inhibitors. We used Libdock to screen the structure and performed toxicity predictions, ADME (absorption, distribution, metabolism, excretion) to predict small molecules' pharmacological and toxicological properties. To assess the binding mechanism and affinity between the mTORC1 dimer and the ligand, molecular docking was performed. Then, the pharmacophore of small molecules in the docking conformation with the protein was supplemented by Schrodinger. Additionally, molecular dynamics simulations were conducted to assess if the ligand-receptor complex was stable in a natural environment. Furthermore, an experiment was performed to verify the inhibitory effect of compound 1 and compound 2 on mTOR protein. All in all, the study provides a hand of candidate drugs as well as pharmacological properties, which can play an essential role in mTORC1 inhibitors.

Indexed as

AnimalsApoptosisAutophagyFemaleHumansIschemic StrokeMaleMechanistic Target of Rapamycin Complex 1MiceMolecular Docking SimulationNeuronsNeuroprotective AgentsRatsReperfusion InjurySignal TransductionSirolimusMechanistic Target of Rapamycin Complex 1Neuroprotective AgentsSirolimusTOR Serine-Threonine Kinasesautophagycerebral ischemia/reperfusion injury (CIRI)mTORC1 inhibitorsthe mammalian target of rapamycin (mTORC1)

Identifiers

PMID34343111
PMCPMC8386574
OpenAlexW3191714783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.